The NFL will spend up to $1 million funding up to five studies that will examine how to better help players ease their pain and find alternatives to opioids.
Among those potential alternatives: marijuana and other cannabis-derived products.
The league announced its call for research proposals Tuesday. The league and the NFL Players Association formed a joint pain management committee in 2019 to help find alternatives to opioids and give players and league medical staffs information on pain management.
Dr. Allen Sills, the NFL's chief medical officer, said there are a lot of great ideas and important research that need to be funded.
“This is really not an NFL issue or a sports issue,” Sills said. "This is a societal issue, which is how can we better understand and treat pain and what are the alternatives that may be out there for treatment in addition to opioids which have long been used.”
Some retired NFL players, including Nate Jackson and Kyle Turley, have spoken out about their use of marijuana during their time in the league and said it's a better way of managing pain than the drugs prescribed by team doctors. The league prohibits marijuana use by players.
Jeff Miller, the NFL’s executive vice president overseeing player health and safety, said the league’s policy on substance abuse is not changing, with Tuesday’s announcement focused only on proposals and research.
The pain management committee held two forums in 2020 to learn more about cannabidiol science and manufacturing and now wants more information on how cannabinoids not only affect pain but the performance of NFL players.
Dr. Kevin Hill is co-chairman of the joint pain management committee and wrote a book titled “Marijuana: The Unbiased Truth about the World's Most Popular Weed." He said players have been asking about cannabis and cannabidiol CBD. Hill said they've tried to provide the best information on a controversial topic.
“Unfortunately, the level of interest right now far exceeds the level of evidence supporting the use of medical cannabis for pain,” Hill said.
Hill, also director of addiction psychiatry at Beth Israel Deaconess Medical Center and associate professor of psychiatry at Harvard Medical School, said there are flaws in each of the controlled trials despite some evidence supporting the use of medical cannabis for pain.
“That’s why we put out this request for proposals so that we can collectively with the PA, the players association, move towards finding better treatments for pain. Those treatments may include cannabis, and they may include CBD,” Hill said.
The NFL opened the application process Tuesday. The league wants initial proposals studying how cannabinoids can help players manage pain daily and after surgery, how cannabis or cannabinoids affect players' athletic performance, and how other non-pharmaceutical treatments can benefit players.
Proposals must be submitted by July 31 with the pain management committee paring down submissions for formal presentations. Those will presented in November with a final decision the week of Dec. 6.
Ellen Fitzsimmons-Craft, assistant professor of psychiatry at Washington University School of Medicine, joins Cheddar News to discuss how chatbots can help prevent eating disorders and the research that uncovered these findings.
Shoulder injuries are one of the most common orthopedic injuries – and they're also one of the most commonly ignored. But chimpanzees, with whom we share nearly 99% of our DNA, don’t encounter the same issues we do. So why are human shoulders such a design disaster? Well, we can trace the answer back to a very particular moment in our evolution.
As the Omicron variant continues to sweep across the country. The US Supreme Court is expected to hear arguments at the end of this week on whether or not the Biden administration can force private companies to vaccinate or test millions of their employees. In addition, the National Nurses United has spearheaded legal action to protect nurses and health care workers, patients, and the public while on the job. President of the National Nurses Union, Zenei Cortez, joined Cheddar to discuss more.
Digital medical care provider Pear Therapeutics rang the closing bell on the Nasdaq Friday and President and CEO Dr. Corey McCann, joined Cheddar to talk about how the company plans to grow the business of software-based therapeutics and how the first FDA authorized prescription digital therapeutics company will go about treating illnesses like insomnia and addiction. "These really are pieces of software. In many cases, they're apps and in the cases of our addiction products, these are based on something called cognitive behavioral therapy or CBT," he said. "These products change the patient's brain circuitry to help them be abstinent, to help them stay in treatment, and that's exactly what we see in randomized clinical trials and that's what we see in the real world." He also addressed the ongoing mental health crises brought on by the pandemic. **copy updated to remove IPO information as Pear Therapeutics went public in December**
Jake Carbone, senior data analyst at InfluenceMap joins Cheddar News to talk about a new report by The Guardian and InfluenceMap that reveals how companies are creating fossil fuel ads designed to look like Google search results.
Satellite launch service Virgin Orbit has gone public on the Nasdaq via a SPAC merger with NextGen Acquisitions with a valuation of about $3.2 billion. CEO Dan Hart joined Cheddar's "Between Bells" from in front of his LauncherOne rocket in New York City's Times Square to talk about what's next after the IPO, an upcoming "Above the Clouds" mission to deliver commercial and national security payloads, and the benefits of their rockets being launched from commercial 747 aircraft. "We can launch anywhere in the world," he said. "There are almost 80 space agencies across the world, for instance, and about 10 of them have space launch. We can give them a space flight capability overnight by taking a runway and turning it into a spaceport."
The year 2021 saw numerous natural disasters around the world, including extreme heat and wildfires, rare deep freezes, and historic flooding. This year's United Nations COP26 conference was key for getting world leaders on board with emissions reductions and other climate-focused policies as the UN Secretary-General said the agency's report on global warming is a 'code red for humanity.' In the U.S., President Joe Biden has focused most of his domestic agenda on slashing emissions and building climate-focused infrastructure. Guests from The Economist, UNC-Chapel Hill, Global Rescue, and more join Cheddar Climate's year-end special to discuss how the climate changed in 2021, and what to expect in 2022.
Digital mental health company Little Otter recently announced it closed a $22 million Series A round. Little Otter was founded in 2020 by a mother-daughter team, which based the company on the idea that a child's mental health can only be addressed by treating the whole family through technology available to everyone. Little Otter CEO and co-founder Rebecca Egger and her mother, Little Otter Chief Medical and Scientific Officer and co-founder Dr. Helen Egger joined Cheddar News' Closing Bell to discuss.
Among all the other events of the last few years, you may have missed this one: Spermageddon. This is the fun name for the idea that sperm counts among mainly ‘Western’ men are in freefall. The Spermageddon hype began with the publication of a 2017 study showing a nearly 60% drop in overall sperm counts in men living in North America, Europe, Australia, and New Zealand.
But four years later, it seems that Spermageddon has been overblown. By a lot. And all that hype has obscured the real issue behind declining male fertility.
Covid-19 has changed the way we view wellness. Jillian Hughes, communications director of Mental Health America, joins Cheddar News to discuss breaking the stigma around mental health. Justin Davis, CEO and co-founder of Spectrum Labs, weighs in on how social media impacts our wellbeing. Lastly, Precision Nutrition CEO Timothy Jones advices us on what trends to watch in 2022.
